Cambrex Invests $5 Million in New Laboratory Expansion at its Karlskoga, Sweden Facility
May 31 2018 - 8:00AM
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small
molecule innovator and generic Active Pharmaceutical Ingredients
(APIs), today announced that it is to commence a $5 million
expansion of laboratory facilities at its Karlskoga, Sweden site,
to augment capability and capacity for process development and
scale up, handling of potent substances, crystallization studies
and solid phase characterization. Construction work on the three
story, 600 m2 building will commence at the end of Q2 2018, with
completion due in Q2 2019.
The expansion will create space for a new
technical laboratory with walk-in hoods for large scale laboratory
syntheses up to 10 liters, where engineers and chemists will
undertake tech transfer studies. The new investment will also
enable handling of potent substances at a large laboratory scale,
high pressure reactions and parallel synthesis for API route
scouting and development.
In addition to the technical laboratory, the
expansion will feature two analytical development and quality
control laboratories and additional office space for 12 additional
scientists and chemists, taking the total headcount to 60.
“We have a rich history in chemistry at our
Karlskoga site, dating back 120 years to Alfred Nobel himself in
1896,” commented Bjarne Sandberg, Managing Director, Cambrex
Karlskoga. He added, “The new laboratory expansion will enhance our
ability to provide global customers with scientific and chemical
excellence.”
In 2017 Cambrex announced that it had upgraded
its continuous flow capabilities in Karlskoga with a dedicated
commercial-scale unit, capable of producing multiple metric tons of
high purity API intermediates per annum. To complement these
capabilities, the company also completed the installation of
multiple continuous flow reactor platforms at its process
development facility in High Point, North Carolina. This investment
is focused on the rapid and successful development of processes to
supply clinical as well as commercial demand for chemical
syntheses.
About Cambrex
Cambrex Corporation is an innovative life
sciences company that provides products, services and technologies
to accelerate the development and commercialization of small
molecule therapeutics. The Company offers Active Pharmaceutical
Ingredients (APIs), advanced intermediates and enhanced drug
delivery products for branded and generic pharmaceuticals.
Development and manufacturing capabilities include enzymatic
biotransformations, high potency APIs, high energy chemical
synthesis, controlled substances and continuous processing. For
more information, please visit www.cambrex.com.
Contact:
Alex
Maw
Director, Marketing and
Communications
Tel: +44 7803 443
155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cambrex (NYSE:CBM)
Historical Stock Chart
From Apr 2023 to Apr 2024